Our custom in vivo glycobiology disease model service offers tailored solutions for researchers seeking to investigate diseases related to sugars or glycosylation. Leveraging cutting-edge techniques and expertise, we specialize in Developing High-quality Custom Models to meet your specific research needs, accelerating scientific discovery in glycobiology.
Advanced custom services offered by CD BioGlyco provide researchers with powerful tools to create tailored disease models that accurately recapitulate glycobiology-related disorders, including diabetes, neurodegenerative diseases, cancer, cardiovascular disorders, metabolic syndrome, and rare genetic disorders. With our expertise in molecular biology, genome editing, and transgenic technologies, we empower researchers to explore novel therapeutic strategies and accelerate the development of innovative treatments for debilitating diseases. Moreover, CD BioGlyco also provides the glycobiology disease model construction service for our clients to choose from. based on our in vivo glycobiology disease model, we offer clients the in vivo glycobiology disease model screening service.
Our skilled team uses embryonic stem cell technology to precisely modify the genomes of mice, allowing for the generation of genetically engineered mouse models (GEMMs) with targeted gene mutations or knockouts relevant to glycobiology and associated diseases. This approach enables the study of gene function, disease mechanisms, and therapeutic interventions in vivo.
Leveraging the revolutionary CRISPR-Cas technology, our experts offer CRISPR-Pro-based services for the generation of genetically modified mice with unparalleled efficiency and precision. Whether it involves gene editing, knock-in, knock-out, or point mutations, our CRISPR-based approach facilitates rapid and specific genome modifications, accelerating research in glycobiology and disease modeling.
Our transgenic services enable the generation of mice or rats expressing foreign genes of interest under the control of tissue-specific or inducible promoters relevant to glycobiology research. By introducing transgenes into the genome of rodents, researchers can investigate the functional consequences of gene overexpression or gain-of-function mutations in vivo, elucidating their roles in disease pathogenesis and therapeutic targets.
CD BioGlyco's custom in vivo glycobiology disease model service offers valuable applications across various research areas, here are some of the disease research that our models can be used in.
DOI: https://doi.org/10.1093/glycob/cwaa018
Technology: Mass spectrometry (MS), Flow cytometry, ELISA, Animal model
Journal: Glycobiology
IF: 4.3
Published: 2020
Results: This review highlights the critical role of antibody glycosylation in infectious diseases, impacting antibody function, inflammation, and disease severity. It suggests that studying antibody glycosylation in vivo disease models, such as those used in the in vivo glycobiology disease model, can provide valuable insights into the immune response to pathogens and guide the development of vaccines and therapeutics that leverage antibody glycosylation to combat infectious diseases.
Fig.1 Potential model by which autoimmune diseases and chronic infections drive inflammatory IgG release. (Irvine & Alter, 2020)
At CD BioGlyco, our commitment is to provide you with high-quality custom disease models that meet your needs and contribute to the advancement of glycobiology research. Please feel free to contact us to learn more and discuss your research requirements.
Reference